ΠΠ·ΡΡΠ΅Π½ΠΈΠ΅ Π±ΠΈΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΠ΅ΠΉ ΠΌΡΡΠ°Π½ΡΠ½ΡΡ ΡΠΎΡΠΌ Π±Π΅Π»ΠΊΠ° Ρ53
ΠΠΈΡΡΠ΅ΡΡΠ°ΡΠΈΡ
ΠΠΎΠ»ΡΡΠ΅Π½Ρ ΠΏΠ°Π½Π΅Π»ΠΈ Π»ΠΈΠ½ΠΈΠΉ ΠΊΠ»Π΅ΡΠΎΠΊ, ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΡΡΡΡΠΈΡ Ρ53 ΠΏΠΎΠ΄ Π΄Π΅ΠΊΡΠ°ΠΌΠ΅ΡΠ°Π·ΠΎΠ½ ΠΈΠ»ΠΈ ΡΠ΅ΡΡΠ°ΡΠΈΠΊΠ»ΠΈΠ½ ΡΠ΅Π³ΡΠ»ΠΈΡΡΠ΅ΠΌΡΠΌΠΈ ΠΏΡΠΎΠΌΠΎΡΠΎΡΠ°ΠΌΠΈ. Π ΡΡΠΈΡ ΡΠΈΡΡΠ΅ΠΌΠ°Ρ Π±ΡΠ»ΠΎ ΡΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½ΠΎ: Π°) Π‘ΡΡΠ΅ΡΡΠ²ΡΠ΅Ρ ΠΏΠΎΠ·ΠΈΡΠΈΠ²Π½Π°Ρ ΠΊΠΎΡΡΠ΅Π»ΡΡΠΈΡ ΠΌΠ΅ΠΆΠ΄Ρ ΡΠΊΡΠΏΡΠ΅ΡΠΈΠ΅ΠΉ ΠΌΡΡΠ°Π½ΡΠ½ΠΎΠ³ΠΎ Ρ53 ΠΈ ΠΏΠΎΠ²ΡΡΠ΅Π½ΠΈΠ΅ΠΌ ΡΡΠ°Π½ΡΠΊΡΠΈΠΏΡΠΈΠΈ ΠΎΠ±Π½Π°ΡΡΠΆΠ΅Π½Π½ΡΡ Π³Π΅Π½ΠΎΠ². Π±) ΠΠ»Ρ Π°ΠΊΡΠΈΠ²Π°ΡΠΈΠΈ Π³Π΅Π½ΠΎΠ² Π΄Π£Π’Π€Π°Π·Ρ, 21ΠΊΠ, № 38 ΠΈ NAP1 ΠΌΡΡΠ°Π½ΡΠ½ΡΠΌΠΈ Π±Π΅Π»ΠΊΠ°ΠΌΠΈ Ρ53 ΡΡΠ΅Π±ΡΠ΅ΡΡΡ Π½Π΅ΠΏΠΎΠ²ΡΠ΅ΠΆΠ΄Π΅Π½Π½ΡΠΉ N-ΠΊΠΎΠ½ΡΠ΅Π²ΠΎΠΉ ΡΡΠ°Π½ΡΠΊΡΠΈΠΏΡΠΈΠΎΠ½Π½ΡΠΉ Π΄ΠΎΠΌΠ΅Π½. Π²… Π§ΠΈΡΠ°ΡΡ Π΅ΡΡ >
- Π‘ΠΎΠ΄Π΅ΡΠΆΠ°Π½ΠΈΠ΅
- ΠΡΠ΄Π΅ΡΠΆΠΊΠ°
- ΠΠΈΡΠ΅ΡΠ°ΡΡΡΠ°
- ΠΡΡΠ³ΠΈΠ΅ ΡΠ°Π±ΠΎΡΡ
- ΠΠΎΠΌΠΎΡΡ Π² Π½Π°ΠΏΠΈΡΠ°Π½ΠΈΠΈ
Π‘ΠΎΠ΄Π΅ΡΠΆΠ°Π½ΠΈΠ΅
- Π‘ΠΎΠ΄Π΅ΡΠΆΠ°Π½ΠΈΠ΅
- Π‘ΠΏΠΈΡΠΎΠΊ ΡΠΎΠΊΡΠ°ΡΠ΅Π½ΠΈΠΉ
- 1. ΠΠ±Π·ΠΎΡ Π»ΠΈΡΠ΅ΡΠ°ΡΡΡΡ
- ΠΠ²Π΅Π΄Π΅Π½ΠΈΠ΅
- 1. 1. ΠΠ±ΡΠ°Ρ Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΡΡΠΈΠΊΠ° Π°Π½ΡΠΈΠΎΠ½ΠΊΠΎΠ³Π΅Π½Π° Ρ
- 1. 1. 1. ΠΠΎΠ»Π΅ΠΊΡΠ»ΡΡΠ½Π°Ρ ΠΎΡΠ³Π°Π½ΠΈΠ·Π°ΡΠΈΡ Π³Π΅Π½Π° Ρ
- 1. 1. 2. ΠΡΡΠ°ΡΠΈΠΈ Π³Π΅Π½Π° Ρ53 Π² ΠΎΠΏΡΡ ΠΎΠ»ΡΡ ΡΠ΅Π»ΠΎΠ²Π΅ΠΊΠ°
- 1. 1. 3. ΠΠΎΠΌΠ΅Π½Π½Π°Ρ ΠΎΡΠ³Π°Π½ΠΈΠ·Π°ΡΠΈΡ Π±Π΅Π»ΠΊΠ° Ρ
- 1. 1. 4. Π Π΅Π½ΡΠ³Π΅Π½ΠΎΡΡΡΡΠΊΡΡΡΠ½ΡΠΉ Π°Π½Π°Π»ΠΈΠ· Ρ
- 1. 2. ΠΠΈΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠ΅ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ Π±Π΅Π»ΠΊΠ° Ρ
- 1. 2. 1. ΠΠ΅Π»ΠΎΠΊ Ρ53 ΡΡΠ°Π½ΡΠΊΡΠΈΠΏΡΠΈΠΎΠ½Π½ΡΠΉ Π°ΠΊΡΠΈΠ²Π°ΡΠΎΡ ΠΈ ΡΠ΅ΠΏΡΠ΅ΡΡΠΎΡ
- 1. 2. 2. Π£ΡΠ°ΡΡΠΈΠ΅ Ρ53 Π² ΡΠ΅Π³ΡΠ»ΡΡΠΈΠΈ ΡΠ²Π΅ΡΠΎΡΠ½ΡΡ
ΡΠΎΡΠ΅ΠΊ ΠΊΠ»Π΅ΡΠΎΡΠ½ΠΎΠ³ΠΎ ΡΠΈΠΊΠ»Π°
- 1. 2. 2. 1. Π Π΅Π³ΡΠ»ΡΡΠΈΡ G1/S ΠΏΠ΅ΡΠ΅Ρ ΠΎΠ΄Π° ΠΊΠ»Π΅ΡΠΎΡΠ½ΠΎΠ³ΠΎ ΡΠΈΠΊΠ»Π°. Π 53-Π·Π°Π²ΠΈΡΠΈΠΌΡΠΉ Gl Π°ΡΠ΅ΡΡ
- 1. 2. 2. 2. Π 53-Π·Π°Π²ΠΈΡΠΈΠΌΡΠΉ G2 Π°ΡΠ΅ΡΡ
- 1. 2. 3. ΠΠ΅Π½Ρ-ΠΌΠΈΡΠ΅Π½ΠΈ Ρ53 ΠΈ Ρ53-Π·Π°Π²ΠΈΡΠΈΠΌΠΎΠ³ΠΎ Π°ΠΏΠΎΠΏΡΠΎΠ·Π°
- 1. 2. 4. ΠΠ΅Π½Ρ-ΠΌΠΈΡΠ΅Π½ΠΈ Ρ53, ΡΡΠ½ΠΊΡΠΈΡ ΠΊΠΎΡΠΎΡΡΡ Π½Π΅ Π²ΡΡΡΠ½Π΅Π½Π°
- 1. 3. ΠΠΊΡΠΈΠ²Π°ΡΠΈΡ ΠΈ ΠΈΠ½Π³ΠΈΠ±ΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅ ΡΡΠ°Π½ΡΠΊΡΠΈΠΏΡΠΈΠΎΠ½Π½ΠΎΠ³ΠΎ ΡΠ°ΠΊΡΠΎΡΠ° — Ρ
- 1. 3. 1. ΠΠ·Π°ΠΈΠΌΠΎΠ΄Π΅ΠΉΡΡΠ²ΠΈΠ΅ Ρ ΠΊΠ»Π΅ΡΠΎΡΠ½ΡΠΌΠΈ Π±Π΅Π»ΠΊΠ°ΠΌΠΈ Mdm2, JNK, WT1 ΠΈ ATM
- 1. 3. 2. ΠΠΎΠ°ΠΊΡΠΈΠ²Π°ΡΠΎΡΡ Ρ
- 1. 3. 3. ΠΠ·Π°ΠΈΠΌΠΎΠ΄Π΅ΠΉΡΡΠ²ΠΈΠ΅ Ρ53 Ρ Π²ΠΈΡΡΡΠ½ΡΠΌΠΈ ΠΎΠ½ΠΊΠΎΠ±Π΅Π»ΠΊΠ°ΠΌΠΈ
- 1. 3. 4. ΠΠΎΡΡΡΠ°Π½ΡΠ»ΡΡΠΈΠΎΠ½Π½ΡΠ΅ ΠΌΠΎΠ΄ΠΈΡΠΈΠΊΠ°ΡΠΈΠΈ Ρ53. 54 1.3.4.1. Π€ΠΎΡΡΠΎΡΠΈΠ»ΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅
- 1. 3. 4. 2. ΠΡΠ΅ΡΠΈΠ»ΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅ Ρ
- 1. 1. ΠΠ±ΡΠ°Ρ Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΡΡΠΈΠΊΠ° Π°Π½ΡΠΈΠΎΠ½ΠΊΠΎΠ³Π΅Π½Π° Ρ
- 1. 4. Π‘ΠΈΡΡΠ΅ΠΌΡ Π΄Π΅Π³ΡΠ°Π΄Π°ΡΠΈΠΈ Ρ
- 1. 5. ΠΠΈΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠ΅ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΠΌΡΡΠ°Π½ΡΠ½ΡΡ
ΡΠΎΡΠΌ Π±Π΅Π»ΠΊΠ° Ρ
- 1. 5. 1. ΠΠΎΠΎΠΏΠ΅ΡΠ°ΡΠΈΡ ΠΌΡΡΠ°Π½ΡΠ½ΠΎΠ³ΠΎ Π±Π΅Π»ΠΊΠ° Ρ53 Ρ ΠΎΠ½ΠΊΠΎΠ³Π΅Π½Π°ΠΌΠΈ
- 1. 5. 2. Π£ΡΠ°ΡΡΠΈΠ΅ ΠΌΡΡΠ°Π½ΡΠ½ΠΎΠ³ΠΎ Ρ53 Π² ΠΈΠΌΠΌΠΎΡΡΠ°Π»ΠΈΠ·Π°ΡΠΈΠΈ ΠΊΠ»Π΅ΡΠΎΠΊ
- 1. 5. 3. ΠΠΎΠ·ΠΈΡΠΈΠ²Π½Π°Ρ ΡΠ΅Π³ΡΠ»ΡΡΠΈΡ ΡΠΈΠ½ΡΠ΅Π·Π° ΠΠΠ ΠΌΡΡΠ°Π½ΡΠ½ΡΠΌ Π±Π΅Π»ΠΊΠΎΠΌ Ρ
- 1. 5. 4. ΠΠ·Π°ΠΈΠΌΠΎΠ΄Π΅ΠΉΡΡΠ²ΠΈΠ΅ ΠΌΡΡΠ°Π½ΡΠ½ΠΎΠ³ΠΎ Ρ53 Ρ Π±Π΅Π»ΠΊΠ°ΠΌΠΈ ΡΠ΅ΠΏΠ»ΠΎΠ²ΠΎΠ³ΠΎ ΡΠΎΠΊΠ°
- 1. 5. 5. Π‘ΠΏΠ΅ΡΠΈΡΠΈΡΠ΅ΡΠΊΠΎΠ΅ ΡΠ²ΡΠ·ΡΠ²Π°Π½ΠΈΠ΅ ΠΌΡΡΠ°Π½ΡΠ½ΠΎΠ³ΠΎ Ρ53 Ρ ΡΡΠ΄ΠΎΠΌ ΠΊΠ»Π΅ΡΠΎΡΠ½ΡΡ Π±Π΅Π»ΠΊΠΎΠ²
- 1. 5. 6. ΠΠ·Π°ΠΈΠΌΠΎΠ΄Π΅ΠΉΡΡΠ²ΠΈΠ΅ ΠΌΡΡΠ°Π½ΡΠ½ΡΡ ΡΠΎΡΠΌ Π±Π΅Π»ΠΊΠ° Ρ53 Ρ ΠΠΠ
- 1. 5. 7. Π₯Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΡΡΠΈΠΊΠ° ΡΡΠ°Π½ΡΠ°ΠΊΡΠΈΠ²ΠΈΡΡΡΡΠΈΡ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΠ΅ΠΉ ΠΌΡΡΠ°Π½ΡΠ½ΡΡ ΡΠΎΡΠΌ Ρ
- 1. 6. ΠΠΎΠ½ΡΠΎΡΠΌΠ°ΡΠΈΠΈ ΠΌΡΡΠ°Π½ΡΠ½ΡΡ ΡΠΎΡΠΌ Π±Π΅Π»ΠΊΠ° Ρ
- 1. 7. ΠΡΡΠ°Π½ΡΠ½ΡΠΉ Ρ53-Π΄ΠΎΠΌΠΈΠ½Π°Π½ΡΠ½ΡΠΉ ΠΈΠ»ΠΈ ΡΠ΅ΡΠ΅ΡΡΠΈΠ²Π½ΡΠΉ ΠΎΠ½ΠΊΠΎΠ³Π΅Π½
- 1. 8. Π‘ΡΠ°Π±ΠΈΠ»ΠΈΠ·Π°ΡΠΈΡ ΠΌΡΡΠ°Π½ΡΠ½ΠΎΠ³ΠΎ Π±Π΅Π»ΠΊΠ° Ρ
- 1. 9. Π‘ΡΠ±ΠΊΠ»Π΅ΡΠΎΡΠ½Π°Ρ Π»ΠΎΠΊΠ°Π»ΠΈΠ·Π°ΡΠΈΡ Π±Π΅Π»ΠΊΠ° Ρ
- 2. 1. ΠΡΠ»ΡΡΠΈΠ²ΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅ ΠΊΠ»Π΅ΡΠΎΡΠ½ΡΡ Π»ΠΈΠ½ΠΈΠΉ
- 2. 2. ΠΠΎΠ»ΡΡΠ΅Π½ΠΈΠ΅ ΠΏΠ°Π½Π΅Π»Π΅ΠΉ Π»ΠΈΠ½ΠΈΠΉ ΠΊΠ»Π΅ΡΠΎΠΊ ΡΠ΅Π»ΠΎΠ²Π΅ΠΊΠ° ΠΈ ΠΌΡΡΠΈ, ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΡΡΡΡΠΈΡ Ρ53 Π΄ΠΈΠΊΠΎΠΉ ΠΈ ΠΌΡΡΠ°Π½ΡΠ½ΡΡ ΡΠΎΡΠΌ ΠΏΠΎΠ΄ ΠΊΠΎΠ½ΡΡΠΎΠ»Π΅ΠΌ Π³ΠΎΡΠΌΠΎΠ½-Π·Π°Π²ΠΈΡΠΈΠΌΠΎΠ³ΠΎ ΠΈΠ»ΠΈ ΡΠ΅ΡΡΠ°ΡΠΈΠΊΠ»ΠΈΠ½-ΡΠ΅Π³ΡΠ»ΠΈΡΡΠ΅ΠΌΠΎΠ³ΠΎ ΠΏΡΠΎΠΌΠΎΡΠΎΡΠ°
- 2. 3. ΠΠΌΠΌΡΠ½ΠΎΠΏΡΠ΅ΡΠΈΠΏΠΈΡΠ°ΡΠΈΡ
- 2. 4. Π€ΡΠ°ΠΊΡΠΈΠΎΠ½ΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅ Π±Π΅Π»ΠΊΠΎΠ² Π² ΠΏΠΎΠ»ΠΈΠ°ΠΊΡΠΈΠ»Π°ΠΌΠΈΠ΄Π½ΠΎΠΌ Π³Π΅Π»Π΅
- 2. 5. ΠΠ΅ΡΠ΅Π½ΠΎΡ Π±Π΅Π»ΠΊΠΎΠ² ΠΈΠ· Π³Π΅Π»Π΅ΠΉ Π½Π° Π½ΠΈΡΡΠΎΡΠ΅Π»Π»ΡΠ»ΠΎΠ·Π½ΡΠ΅ ΡΠΈΠ»ΡΡΡΡ ΠΈ ΠΈΠΌΠΌΡΠ½ΠΎΠ΄Π΅ΡΠ΅ΠΊΡΠΈΡ Ρ
- 2. 6. ΠΠ°ΠΊΡΠ΅ΡΠΈΠ°Π»ΡΠ½ΡΠ΅ ΡΡΠ°ΠΌΠΌΡ, ΠΏΠ»Π°Π·ΠΌΠΈΠ΄Ρ, ΡΠ΅ΡΡΠΎΠ²ΠΈΡΡΡΠ½ΡΠ΅ Π²Π΅ΠΊΡΠΎΡΠ°
- 2. 7. ΠΠΎΠ»ΡΡΠ΅Π½ΠΈΠ΅ ΠΊΠΎΠΌΠΏΠ΅ΡΠ΅Π½ΡΠ½ΡΡ ΠΊΠ»Π΅ΡΠΎΠΊ DH
- 2. 8. ΠΡΠ΄Π΅Π»Π΅Π½ΠΈΠ΅ ΠΏΠ»Π°Π·ΠΌΠΈΠ΄Π½ΠΎΠΉ ΠΠΠ
- 2. 8. 1. ΠΡΠ΅ΠΏΠ°ΡΠ°ΡΠΈΠ²Π½ΠΎΠ΅ Π²ΡΠ΄Π΅Π»Π΅Π½ΠΈΠ΅ ΠΏΠ»Π°Π·ΠΌΠΈΠ΄Π½ΠΎΠΉ ΠΠΠ
- 2. 8. 2. ΠΠ½Π°Π»ΠΈΡΠΈΡΠ΅ΡΠΊΠΎΠ΅ Π²ΡΠ΄Π΅Π»Π΅Π½ΠΈΠ΅ΠΏΠ»Π°Π·ΠΌΠΈΠ΄Π½ΠΎΠΉ ΠΠΠ
- 2. 9. ΠΠ±ΡΠ°Π±ΠΎΡΠΊΠ° ΠΠΠ ΡΠ΅ΡΡΡΠΈΠΊΡΠΈΠΎΠ½Π½ΡΠΌΠΈ ΡΠ½Π΄ΠΎΠ½ΡΠΊΠ»Π΅Π°Π·Π°ΠΌΠΈ
- 2. 10. Π€ΡΠ°ΠΊΡΠΈΠΎΠ½ΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅ ΠΠΠ Π² Π°Π³Π°ΡΠΎΠ·Π½ΡΡ Π³Π΅Π»ΡΡ
- 2. 11. ΠΠ·Π²Π»Π΅ΡΠ΅Π½ΠΈΠ΅ ΠΠΠ ΠΈΠ· Π°Π³Π°ΡΠΎΠ·Π½ΡΡ Π³Π΅Π»Π΅ΠΉ
- 2. 12. Π‘ΡΠ±ΠΊΠ»ΠΎΠ½ΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅ ΡΡΠ°Π³ΠΌΠ΅Π½ΡΠΎΠ² ΠΠΠ Π² Π²Π΅ΠΊΡΠΎΡΠ° pPS-neo, pSIT-neo, pMMTV
- 2. 12. 1. ΠΠΎΠ»ΡΡΠ΅Π½ΠΈΠ΅ Π²Π΅ΠΊΡΠΎΡΠ½ΠΎΠΉ ΠΠΠ
- 2. 12. 2. Π Π΅Π°ΠΊΡΠΈΡ Π»ΠΈΠ³ΠΈΡΠΎΠ²Π°Π½ΠΈΡ
- 2. 13. Π’ΡΠ°Π½ΡΡΠΎΡΠΌΠ°ΡΠΈΡ ΠΊΠΎΠΌΠΏΠ΅ΡΠ΅Π½ΡΠ½ΡΡ ΠΊΠ»Π΅ΡΠΎΠΊ E. Coli ΠΏΠ»Π°Π·ΠΌΠΈΠ΄Π½ΠΎΠΉ ΠΠΠ
- 2. 14. Π’ΡΠ°Π½ΡΡΠ΅ΠΊΡΠΈΡ ΡΠ΅ΡΡΠΎΠ²ΠΈΡΡΡΠ½ΡΡ ΠΈ ΠΏΠ»Π°Π·ΠΌΠΈΠ΄Π½ΡΡ ΠΊΠΎΠ½ΡΡΡΡΠΊΡΠΎΠ² ΠΌΠ΅ΡΠΎΠ΄ΠΎΠΌ ΠΊΠ°Π»ΡΡΠΈΠΉ-ΡΠΎΡΡΠ°ΡΠ½ΠΎΠΉ ΠΏΡΠ΅ΡΠΈΠΏΠΈΡΠ°ΡΠΈΠΈ
- 2. 15. ΠΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΠ΅ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΡΡΠ°Π½ΡΡΠ΅ΠΊΡΠΈΠΈ ΠΈ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΈ ΠΏΠΎ ΡΠ»ΡΠΎΡΠΈΡΡΠ΅Π½ΡΠΈΠΈ Π·Π΅Π»Π΅Π½ΠΎΠ³ΠΎ Π±Π΅Π»ΠΊΠ°
- 2. 16. ΠΠ½ΡΠ΅ΠΊΡΠΈΡ ΠΊΠ»Π΅ΡΠΎΠΊ ΡΠ΅ΠΊΠΎΠΌΠ±ΠΈΠ½Π°Π½ΡΠ½ΡΠΌΠΈ ΡΠ΅ΡΡΠΎΠ²ΠΈΡΡΡΠ°ΠΌΠΈ
- 2. 17. ΠΠΎΠ»ΠΈΠΌΠ΅ΡΠ°Π·Π½Π°Ρ ΡΠ΅ΠΏΠ½Π°Ρ ΡΠ΅Π°ΠΊΡΠΈΡ (ΠΠ¦Π )
- 2. 18. ΠΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΠ΅ Π½ΡΠΊΠ»Π΅ΠΎΡΠΈΠ΄Π½ΠΎΠΉ ΠΏΠΎΡΠ»Π΅Π΄ΠΎΠ²Π°ΡΠ΅Π»ΡΠ½ΠΎΡΡΠΈ ΠΏΠΎ ΠΌΠ΅ΡΠΎΠ΄Ρ Π‘ΡΠ½Π³Π΅ΡΠ°. 86 2.19 ΠΠΊΡΡΡΠ°ΠΊΡΠΈΡ Π ΠΠ ΠΈ Nothern-Π±Π»ΠΎΡΡΠΈΠ½Π³. ?6−87 2.20. ΠΠ΅ΡΠΎΠ΄ ΡΡΠ±ΡΡΠ°ΠΊΡΠΈΠ²Π½ΠΎΠΉ Π³ΠΈΠ±ΡΠΈΠ΄ΠΈΠ·Π°ΡΠΈΠΈ
- 2. 21. ΠΡΠ΄Π΅Π»Π΅Π½ΠΈΠ΅ Π²ΡΡΠΎΠΊΠΎΠΌΠΎΠ»Π΅ΠΊΡΠ»ΡΡΠ½ΠΎΠΉ ΠΠΠ
- 2. 22. ΠΠΈΠ±ΡΠΈΠ΄ΠΈΠ·Π°ΡΠΈΡ ΠΏΠΎ Π‘Π°ΡΠ·Π΅ΡΠ½Ρ
- 2. 23. ΠΠ½Π°Π»ΠΈΠ· Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ Ρ Π»ΠΎΡΠ°ΠΌΡΠ΅Π½ΠΈΠΊΠΎΠ»-Π°ΡΠ΅ΡΠΈΠ»ΡΡΠ°Π½ΡΡΠ΅ΡΠ°Π·Ρ (Π‘ΠΠ’-ΡΠ΅Π°ΠΊΡΠΈΡ)
- 2. 24. ΠΡΠΎΡΡΠ΅Ρ ΡΠ°Π΄ΠΈΠΎΠ°ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ Π² ΠΏΡΠΎΠ±Π°Ρ
- 2. 25. ΠΠ²ΡΠΎΡΠ°Π΄ΠΈΠΎΠ³ΡΠ°ΡΠΈΡ
- 2. 26. ΠΠΎΠΌΠΏΡΡΡΠ΅ΡΠ½ΡΠΉ Π°Π½Π°Π»ΠΈΠ·
Π‘ΠΏΠΈΡΠΎΠΊ Π»ΠΈΡΠ΅ΡΠ°ΡΡΡΡ
- Abarzua, P., J. E. LoSardo, M. L. Gubler, and A. Neri. 1995. Microinjection of monoclonal antibody PAb421 into human SW480 colorectal carcinoma cells restores the transcription activation function to mutant p53. Cancer Res 55:3490−4.
- Abarzua, P., J. E. LoSardo, M. L. Gubler, R. Spathis, Y. A. Lu, A. Felix, and A. Neri.1996. Restoration of the transcription activation function to mutant p53 in human cancer cells. Oncogene 13:2477−82.
- Abrahamson, J. L., J. M. Lee, and A. Bernstein. 1995. Regulation of p53-mediated apoptosis and cell cycle arrest by Steel factor. Mol Cell Biol 15:6953−60.
- Kopnin. 1996. Chromosome changes caused by alterations of p53 expression. Mutat Res 354:12 938.
- Agarwal, M. L., A. Agarwal, W. R Taylor, Z. Q. Wang, E. F. Wagner, and G. R. Stark.1997. Defective induction but normal activation and function of p53 in mouse cells lacking poly-ADP-ribose polymerase. Oncogene 15:1035−41.
- Agoff, S. N., J. Hou, D. I. Linzer, and B. Wu. 1993. Regulation of the human hsp70 promoter by p53. Science 259:84−7.
- An, W. G., M. Kanekal, M. C. Simon, E. Maltepe, M. V. Blagosklonny, and L. M. Neckers.1998. Stabilization of wild-type p53 by hypoxia-inducible factor 1 alpha. Nature 392:405−8.
- Avantaggiati, M. L., V. Ogryzko, K. Gardner, A. Giordano, A. S. Levine, and K. Kelly. 1997. Recruitment ofp300/CBP in p53-dependent signal pathways. Cell 89:1175−84.
- Banin, S., L. Moyal, S. Shieh, Y. Taya, C. W. Anderson, L. Chessa, N. I. Smorodinsky, C. Prives, Y. Reiss, Y. Shiloh, and Y. Ziv. 1998. Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science 281:1674−7.
- Barak, Y., E. Gottlieb, T. Juven-Gershon, and M. Oren. 1994 Regulation of mdm2 expression by p53: alternative promoters produce transcripts with nonidentical translation potential. Genes Dev 8:1739−49.
- Barlow, C., K. D. Brown, C. X. Deng, D. A. Tagle, and A. Wynshaw-Boris. 1997 Atm selectively regulates distinct p53-dependent cell-cycle checkpoint and apoptotic pathways published erratum appears in Nat Genet 1998 Mar-18(3):298., Nat Genet 17:453−6.
- Baudier, J., C. Delphin, D. Grunwald, S. Khochbin, and J. J. Lawrence. 1992. Characterization of the tumor suppressor protein p53 as a protein kinase C substrate and a SI00b-binding protein. Proc Natl Acad Sci U S A 89:11 627−31.
- Bennett, M., K. Macdonald, S. W. Chan, J. P. Luzio, R. Simari, and P. Weissberg.1998. Cell surface trafficking of Fas: a rapid mechanism of p53-mediated apoptosis. Science 282:290−3.
- Bian, J., and Y. Sun. 1997. Transcriptional activation by p53 of the human type IV collagenase (gelatinase A or matrix metalloproteinase 2) promoter. Mol Cell Biol 17:6330−8.
- Bischoff, J. R., P. N. Friedman, D. R. Marshak, C. Prives, and D. Beach. 1990 Human p53 is phosphorylated by p60-cdc2 and cyclin B-cdc2. Proc Natl Acad Sci U S A 87:4766−70.
- Blagosklonny, M. V., W. G. An, L. Y. Romanova, J. Trepel, T. Fojo, and L. Neckers. 1998. p53 inhibits hypoxia-inducible factor-stimulated transcription. J Biol Chem 273:11 995−8.
- Blagosklonny, M. V., J. Toretsky, S. Bohen, and L. Neckers. 1996. Mutant conformation of p53 translated in vitro or in vivo requires functional HSP90. Proc Natl Acad Sci U S A 93:837 983.
- Blagosklonny, M. V., J. Toretsky, and L. Neckers. 1995. Geldanamycin selectively destabilizes and conformationally alters mutated p53. Oncogene 11:933−9.
- Blondal, J. A., and S. Benchimol. 1994. The role of p53 in tumor progression. Semin Cancer Biol 5:177−86.
- Boddy, M. N., P. S. Freemont, and K. L. Borden. 1994. The p53-associated protein MDM2 contains a newly characterized zinc- binding domain called the RING finger. Trends Biochem Sci 19:198−9.
- Brain, R., and J. R. Jenkins. 1994. Human p53 directs DNA strand reassociation and is photolabelled by 8- azido ATP. Oncogene 9:1775−80.
- Buckbinder, L., R. Talbott, S. Velasco-Miguel, I. Takenaka, B. Faha, B. R. Seizinger, and N. Kley. 1995. Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature 377:646−9.
- Buckbinder, L., S. Velasco-Miguel, Y. Chen, N. Xu, R Talbott, L. Gelbert, J. Gao, B. R. Seizinger, J. S. Gutkind, and N. Kley. 1997. The p53 tumor suppressor targets a novel regulator of G protein signaling. Proc Natl Acad Sci U S A 94:7868−72.
- Caelles, C., A. Helmberg, and M. Karin. 1994. p53-dependent apoptosis in the absence of transcriptional activation of p53-target genes see comments. Nature 370:220−3.
- Castedo, M., A. Macho, N. Zamzami, T. Hirsch, P. Marchetti, J. Uriel, and G. Kroemer. 1995. Mitochondrial perturbations define lymphocytes undergoing apoptotic depletion in vivo. Eur J Immunol 25:3277−84.
- Cavenee, W. K., H. J. Scrable, and C. D. James. 1991. Molecular genetics of human cancer predisposition and progression. Mutat Res 247:199−202.
- Chen, J., X. Wu, J. Lin, and A. J. Levine. 1996. mdm-2 inhibits the G1 arrest and apoptosis functions of the p53 tumor suppressor protein. Mol Cell Biol 16:2445−52.
- Chen, X., L. J. Ko, L. Jayaraman, and C. Prives. 1996. p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumor cells. Genes Dev 10:2438−51.
- Chen, Y., P. L. Chen, and W. H. Lee. 1994. Hot-spot p53 mutants interact specifically with two cellular proteins during progression of the cell cycle. Mol Cell Biol 14:6764−72.
- Cheng, J., and M. Haas. 1990. Frequent mutations in the p53 tumor suppressor gene in human leukemia T- cell lines. Mol Cell Biol 10:5502−9.
- Chin, K. V., K. Ueda, L Pastan, and M. M. Gottesman. 1992. Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science 255:459−62.
- Chitpatima, S. T., S. Makrides, R. Bandyopadhyay, and G. Brawerman. 1988 Nucleotide sequence of a major messenger RNA for a 21 kilodalton polypeptide that is under translational control in mouse tumor cells. Nucleic Acids Res 16:2350.
- Cho, Y., S. Gorina, P. D. Jeffrey, and N. P. Pavletich. 1994. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations see comments. Science 265:346−55.
- Chumakov, A. M., C. W. Miller, D. L. Chen, and H. P. Koeffler. 1993 Analysis of p53 transactivation through high-affinity binding sites. Oncogene 8:3005−11.
- Coles, C., A. Condie, U. Chetty, C. M. Steel, H. J. Evans, and J. Prosser. 1992 p53 mutations in breast cancer. Cancer Res 52:5291−8.
- Cook, A., and J. Milner. 1990. Evidence for allosteric variants of wild-type p53, a tumour suppressor protein. Br J Cancer 61:548−52.
- Cordon-Cardo, C., E. Latres, M. Drobnjak, M. R. Oliva, D. Pollack, J. M. Woodruff, V. Marechal, J. Chen, M. F. Brennan, and A. J. Levine. 1994. Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res 54:794−9.
- Crook, T., N. J. Marston, E. A. Sara, and K. H. Vousden. 1994. Transcriptional activation by p53 correlates with suppression of growth but not transformation. Cell 79:817−27.
- Cross, S. M., C. A. Sanchez, C. A. Morgan, M. K. Schimke, S. Ramel, R. L. Idzerda, W. H. Raskind, and B. J. Reid. 1995. A p53-dependent mouse spindle checkpoint. Science 267:1353−6.
- Deb, S., C. T. Jackson, M. A. Subler, and D. W. Martin. 1992. Modulation of cellular and viral promoters by mutant human p53 proteins found in tumor cells. J Virol 66:6164−70.
- Deb, S. P., R. M. Munoz, D. R. Brown, M. A. Subler, and S. Deb. 1994 Wild-type human p53 activates the human epidermal growth factor receptor promoter. Oncogene 9:1341−9.
- Demers, G. W., S. A. Foster, C. L. Halbert, and D. A. Galloway. 1994 Growth arrest by induction of p53 in DNA damaged keratinocytes is bypassed by human papillomavirus 16 E7. Proc Natl Acad Sci U S A 91:4382−6.
- Donato, N. J., and M. Perez. 1998. Tumor necrosis factor-induced apoptosis stimulates p53 accumulation and p21WAFl proteolysis in ME-180 cells. J Biol Chem 273:5067−72.
- Donehower, L. A., M. Harvey, B. L. Slagle, M. J. McArthur, C. A. Montgomery, Jr., J. S. Butel, and A. Bradley. 1992. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356:215−21.
- Elenbaas, B., M. Dobbelstein, J. Roth, T. Shenk, and A. J. Levine. 1996 The MDM2 oncoprotein binds specifically to RNA through its RING finger domain. Mol Med 2:439−51.
- Eliyahu, D., D. Michalovitz, S. Eliyahu, O. Pinhasi-Kimhi, and M. Oren. 1989 Wildtype p53 can inhibit oncogene-mediated focus formation. Proc Natl Acad Sci U S A 86:8763−7.
- Eliyahu, D., A. Raz, P. Gruss, D. Givol, and M. Oren. 1984. Participation of p53 cellular tumour antigen in transformation of normal embryonic cells. Nature 312:646−9.
- Fakharzadeh, S. S., S. P. Trusko, and D. L. George. 1991. Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. Embo J 10:1565−9.
- Farmer, G., J. Bargonetti, H. Zhu, P. Friedman, R. Prywes, and C. Prives. 1992 Wildtype p53 activates transcription in vitro see comments. Nature 358:83−6.
- Fields, S., and S. K. Jang. 1990. Presence of a potent transcription activating sequence in the p53 protein. Science 249:1046−9.
- Finlay, C. A. 1993. The mdm-2 oncogene can overcome wild-type p53 suppression of transformed cell growth. Mol Cell Biol 13:301−6.
- Finlay, C. A., P. W. Hinds, T. H. Tan, D. Eliyahu, M. Oren, and A. J. Levine. 1988 Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol Cell Biol 8:531−9.
- Forrester, K., S. E. Lupoid, V. L. Ott, C. H. Chay, V. Band, X. W. Wang, and C. C. Harris. 1995. Effects of p53 mutants on wild-type p53-mediated transactivation are cell type dependent. Oncogene 10:2103−11.
- Frebourg, T., M. Sadelain, Y. S. Ng, J. Kassel, and S. H. Friend. 1994 Equal transcription of wild-type and mutant p53 using bicistronic vectors results in the wild-type phenotype. Cancer Res 54:878−81.
- Freedman, D. A., and A. J. Levine. 1998. Nuclear export is required for degradation of endogenous p53 by MDM2 and human papillomavirus E6 In Process Citation., Mol Cell Biol 18:7288−93.
- Fuchs, S. Y., V. Adler, T. Buschmann, Z. Yin, X. Wu, S. N. Jones, and Z. Ronai. 1998 JNK targets p53 ubiquitination and degradation in nonstressed cells. Genes Dev 12:2658−63.
- Fuchs, S. Y., V. Adler, M. R Pincus, and Z. Ronai. 1998. MEKK1/JNK signaling stabilizes and activates p53. Proc Natl Acad Sci U S A 95:10 541−6.
- Fukasawa, K., T. Choi, R. Kuriyama, S. Rulong, and G. F. Vande Woude. 1996 Abnormal centrosome amplification in the absence of p53. Science 271:1744−7.
- Funk, W. D., D. T. Pak, R. H. Karas, W. E. Wright, and J. W. Shay. 1992 A transcriptionally active DNA-binding site for human p53 protein complexes. Mol Cell Biol 12:2866−71.
- Giaccia, A. J., and M. B. Kastan. 1998. The complexity of p53 modulation: emerging patterns from divergent signals. Genes Dev 12:2973−83.
- Gibson, C. W., S. R. Rittling, R. R. Hirschhorn, L. Kaczmarek, B. Calabretta, C. D. Stiles, and R. Baserga. 1986. Cell cycle dependent genes inducible by different mitogens in cells from different species. Mol Cell Biochem 71:61−9.
- Ginsberg, D., F. Mechta, M. Yaniv, and M. Oren. 1991. Wild-type p53 can down-modulate the activity of various promoters. Proc Natl Acad Sci U S A 88:9979−83.
- Gloushankova, N., V. Ossovskaya, J. Vasiliev, P. Chumakov, and B. Kopnin. 1997. Changes in p53 expression can modify cell shape of ras-transformed fibroblasts and epitheliocytes. Oncogene 15:2985−9.
- Gossen, M., and H. Bujard. 1992. Tight control of gene expression in mammalian cells by tetracycline- responsive promoters. Proc Natl Acad Sci U S A 89:5547−51.
- Gottlieb, E., and M. Oren. 1998. p53 facilitates pRb cleavage in EL-3-deprived cells: novel pro- apoptotic activity of p53. Embo J 17:3587−96.
- Graeber, T. G., C. Osmanian, T. Jacks, D. E. Housman, C. J. Koch, S. W. Lowe, and A. J. Giaccia. 1996. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours see comments. Nature 379:88−91.
- Gu, W., and R. G. Roeder. 1997. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 90:595−606.
- Gu, W., X. L. Shi, and R. G. Roeder. 1997. Synergistic activation of transcription by CBP and p53. Nature 387:819−23.
- Gualberto, A., and A. S. Baldwin, Jr. 1995. p53 and Spl interact and cooperate in the tumor necrosis factor-induced transcriptional activation of the HIV-1 long terminal repeat. J Biol Chem 270:19 680−3.
- Gualberto, A., M. L. Hixon, T. S. Finco, N. D. Perkins, G. J. Nabel, and A. S. Baldwin,
- Jr. 1995. A proliferative p53-responsive element mediates tumor necrosis factor alpha induction of the human immunodeficiency virus type 1 long terminal repeat. Mol Cell Biol 15:3450−9.
- Haber, D. A., and D. E. Housman. 1991. Rate-limiting steps: the genetics of pediatric cancers. Cell 64:5−8.
- Hainaut, P., N. Rolley, M. Davies, and J. Milner. 1995. Modulation by copper of p53 conformation and sequence-specific DNA binding: role for Cu (II)/Cu (I) redox mechanism. Oncogene 10:27−32.
- Hainaut, P., T. Soussi, B. Shomer, M. Hollstein, M. Greenblatt, E. Hovig, C. C. Harris, and R. Montesano. 1997. Database of p53 gene somatic mutations in human tumors and cell lines: updated compilation and future prospects. Nucleic Acids Res 25:151−7.
- Hall, S. R., L. E. Campbell, and D. W. Meek. 1996. Phosphorylation of p53 at the casein kinase II site selectively regulates p53-dependent transcriptional repression but not transactivation. Nucleic Acids Res 24:1119−26.
- Han, J., P. Sabbatini, D. Perez, L. Rao, D. Modha, and E. White. 1996. The E1B 19Kprotein blocks apoptosis by interacting with and inhibiting the p53-inducible and death-promoting Bax protein. Genes Dev 10:461−77.
- Haupt, Y., R. Maya, A. Kazaz, and M. Oren. 1997. Mdm2 promotes the rapid degradation of p53. Nature 387:296−9.
- Haupt, Y., and M. Oren. 1996. p53-mediated apoptosis: mechanisms and regulation. Behring Inst Mitt :32−59.
- Haupt, Y., S. Rowan, and M. Oren. 1995. p53-mediated apoptosis in HeLa cells can be overcome by excess pRB. Oncogene 10:1563−71.
- Haupt, Y., S. Rowan, E. Shaulian, A. Kazaz, K. Vousden, and M. Oren. 1997 p53 mediated apoptosis in HeLa cells: transcription dependent and independent mechanisms. Leukemia 11 Suppl 3:337−9
- Hermeking, H., C. Lengauer, K. Polyak, T. C. He, L. Zhang, S. Thiagalingam, K. W. Kinzler, and B. Vogelstein. 1997. 14−3-3 sigma is a p53-regulated inhibitor of G2/M progression. Mol Cell 1:3−11.
- Hickman, E. S., S. M. Picksley, and K. H. Vousden. 1994. Cells expressing HPV16 E7 continue cell cycle progression following DNA damage induced p53 activation. Oncogene 9:217 781.
- Hinds, P. W., C. A. Finlay, A. B. Frey, and A. J. Levine. 1987. Immunological evidence for the association of p53 with a heat shock protein, hsc70, in p53-plus-ras-transformed cell lines. Mol Cell Biol 7:2863−9.
- Hollstein, M., T. Soussi, G. Thomas, M. C. von Brevern, and Bartsch, 2nd. 1997 P53 gene alterations in human tumors: perspectives for cancer control. Recent Results Cancer Res 143:369−89.
- Honda, R., H. Tanaka, and H. Yasuda. 1997. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett 420:25−7.
- Hsu, I. C., R. A. Metcalf, T. Sun, J. A. Welsh, N. J. Wang, and C. C. Harris. 1991 Mutational hotspot in the p53 gene in human hepatocellular carcinomas see comments. Nature 350:427−8.
- Hu, M. C., W. R. Qiu, and Y. P. Wang. 1997. JNK1, JNK2 and JNK3 are p53 N-terminal serine 34 kinases. Oncogene 15:2277−87.
- Hubank, M., and D. G. Schatz. 1994. Identifying differences in mRNA expression by representational difference analysis of cDNA. Nucleic Acids Res 22:5640−8.
- Hudson, J. M., R. Frade, and M. Bar-Eli. 1995. Wild-type p53 regulates its own transcription in a cell-type specific manner. DNA Cell Biol 14:759−66.
- Hupp, T. R., and D. P. Lane. 1994. Allosteric activation of latent p53 tetramers. Curr Biol 4:865−75.
- Iggo, R., K. Gatter, J. Bartek, D. Lane, and A. L. Harris. 1990. Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet 335:675−9.
- ΠΠ»ΡΠΈΠ½ΡΠΊΠ°Ρ, Π. Π., E. H. ΠΡΠ³Π°ΡΠ΅Π²Π°, Π. Π. Π‘ΠΎΠΊΠΎΠ²Π°, Π. Π. Π§ΡΠΌΠ°ΠΊΠΎΠ², Π. Π. ΠΠΎΠΏΠ½ΠΈΠ½.1995. Π 53 Ρ ΠΌΡΡΠ°ΡΠΈΠ΅ΠΉ Π² ΠΊΠΎΠ΄ΠΎΠ½Π΅ 273 ΡΠ²Π΅Π»ΠΈΡΠΈΠ²Π°Π΅Ρ Π²Π΅ΡΠΎΡΡΠ½ΠΎΡΡΡ Π°ΠΌΠΏΠ»ΠΈΡΠΈΠΊΠ°ΡΠΈΠΈ Π³Π΅Π½Π° dhfr Π² ΠΊΠ»Π΅ΡΠΊΠ°Ρ Rat-1 ΠΈ Π1Π1215.ΠΠ΅Π½Π΅ΡΠΈΠΊΠ°. 31:611−6.
- Israeli, D., Π. Tessler, Y. Haupt, A. Elkeles, S. Wilder, R. Amson, A. Telerman, and M.
- Oren. 1997. A novel p53-inducible gene, PAG608, encodes a nuclear zinc finger protein whose overexpression promotes apoptosis. Embo J 16:4384−92.
- Jamal, S., and E. B. Ziff. 1995. Raf phosphorylates p53 in vitro and potentiates p53-dependent transcriptional transactivation in vivo. Oncogene 10:2095−101.
- Jayaraman, L., E. Freulich, and C. Prives. 1997. Functional dissection of p53 tumor suppressor protein. Methods Enzymol 283:245−56.
- Jayaraman, L., N. C. Moorthy, K. G. Murthy, J. L. Manley, M. Bustin, and C. Prives.1998. High mobility group protein-1 (HMG-1) is a unique activator of p53. Genes Dev 12:462−72.
- Jenkins, J. R., P. Chumakov, C. Addison, H. W. Sturzbecher, and A. Wade-Evans.1988. Two distinct regions of the murine p53 primary amino acid sequence are implicated in stable complex formation with simian virus 40 T antigen. J Virol 62:3903−6.
- Jenkins, J. R., K. Rudge, and G. A. Currie. 1984. Cellular immortalization by a cDNA clone encoding the transformation- associated phosphoprotein p53. Nature 312:651−4.
- Johnson, T. M., Z. X. Yu, V. J. Ferrans, R. A. Lowenstein, and T. Finkel. 1996 Reactive oxygen species are downstream mediators of p53-dependent apoptosis. Proc Natl Acad SciUS A93:11 848−52.
- Jones, S. N., A. E. Roe, L. A. Donehower, and A. Bradley. 1995. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature 378:206−8.
- Jost, C. A., M. C. Marin, and W. G. Kaelin, Jr. 1997. p73 is a human p53-related protein that can induce apoptosis see comments. Nature 389:191−4.
- Kamijo, T., J. D. Weber, G. Zambetti, F. Zindy, M. F. Roussel, and C. J. Sherr. 1998 Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc Natl Acad Sci U S A 95:8292−7.
- Kamijo, T., F. Zindy, M. F. Roussel, D. E. Quelle, J. R. Downing, R. A. Ashmun, G. Grosveld, and C. J. Sherr. 1997. Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product pl9ARF. Cell 91:649−59.
- Kastan, M. Π., A. I. Radin, S. J. Kuerbitz, Π. Onyekwere, Π‘. A. Wolkow, Π‘. I. Civin, K. D. Stone, T. Woo, Y. Ravindranath, and R. W. Craig. 1991. Levels of p53 protein increase with maturation in human hematopoietic cells. Cancer Res 51:4279−86.
- Kern, S. E., K. W. Kinzler, A. Bruskin, D. Jarosz, P. Friedman, C. Prives, and B. Vogelstein. 1991. Identification of p53 as a sequence-specific DNA-binding protein. Science 252:1708−11.
- ΠΠΎ, L. J., and C. Prives. 1996. p53: puzzle and paradigm. Genes Dev 10:1054−72.
- ΠΠΎ, L. J., S. Y. Shieh, X. Chen, L. Jayaraman, K. Tamai, Y. Taya, C. Prives, and Z. Q. Pan. 1997. p53 is phosphorylated by CDK7-cyclin H in a p36MATl-dependent manner. Mol Cell Biol 17:7220−9.
- ΠΠΎΠ½Π΄ΡΠ°ΡΠΎΠ², P. Π., H. Π. ΠΡΠ·Π½Π΅ΡΠΎΠ², E. H. ΠΡΠ³Π°ΡΠ΅Π²Π°, Π. Π. ΠΠ»ΠΌΠ°Π·ΠΎΠ², Π. Π‘. ΠΡΠ°ΡΠΎΠ»ΠΎΠ², Π. Π. ΠΠΎΠΏΠ½ΠΈΠ½, Π. Π. Π§ΡΠΌΠ°ΠΊΠΎΠ². 1996. Π€ΡΠ½ΠΊΡΠΈΠΎΠ½Π°Π»ΡΠ½Π°Ρ Π³Π΅ΡΠ΅ΡΠΎΠ³Π΅Π½Π½ΠΎΡΡΡ Ρ53-ΡΠ΅ΡΠΏΠΎΠ½ΡΠΈΠ²Π½ΡΡ ΡΠ»Π΅ΠΌΠ΅Π½ΡΠΎΠ². ΠΠΎΠ»Π΅ΠΊΡΠ»ΡΡΠ½Π°Ρ Π±ΠΈΠΎΠ»ΠΎΠ³ΠΈΡ 30:613−20.
- ΠΠΎΠ½Π΄ΡΠ°ΡΠΎΠ² Π . Π., Π. Π. ΠΡΠ³Π°ΡΠ΅Π²Π°, Π. Π. ΠΡΠ·Π½Π΅ΡΠΎΠ², Π. Π. ΠΡΠ°ΡΠΎΠ»ΠΎΠ², Π. Π. ΠΠΎΠΏΠ½ΠΈΠ½, Π. Π. Π§ΡΠΌΠ°ΠΊΠΎΠ². 1996. ΠΠ΅Π½ Π°Π΄Π΅Π½ΠΎΠ·ΠΈΠ½ Π΄Π΅Π·ΠΎΠΌΠΈΠ½Π°Π·Ρ ΡΠ΅Π»ΠΎΠ²Π΅ΠΊΠ° ΡΠΎΠ΄Π΅ΡΠΆΠΈΡ Ρ53-ΡΠ΅ΡΠΏΠΎΠ½ΡΠΈΠ²Π½ΡΠΉ ΡΠ»Π΅ΠΌΠ΅Π½Ρ. ΠΠΠ 346:260−262.
- Koumenis, C., and A. Giaccia. 1997. Transformed cells require continuous activity of RNA polymerase II to resist oncogene-induced apoptosis. Mol Cell Biol 17:7306−16.
- Kubbutat, M. H., S. N. Jones, and K. H. Vousden. 1997. Regulation of p53 stability by Mdm2. Nature 387:299−303.
- Kubbutat, M. H., R. L. Ludwig, M. Ashcroft, and K. H. Vousden. 1998. Regulation of Mdm2-directed degradation by the C terminus of p53. Mol Cell Biol 18:5690−8.
- Kubbutat, M. H., and K. H. Vousden. 1997. Proteolytic cleavage of human p53 by calpain: a potential regulator of protein stability. Mol Cell Biol 17:460−8.
- Kuerbitz, S. J., B. S. Plunkett, W. V. Walsh, and M. B. Kastan. 1992 Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci U S A 89:7491−5.
- Kulesz-Martin, M. F., B. Lisafeld, H. Huang, N. D. Kisiel, and L. Lee. 1994 Endogenous p53 protein generated from wild-type alternatively spliced p53 RNA in mouse epidermal cells. Mol Cell Biol 14:1698−708.
- Lamb, P., and L. Crawford. 1986. Characterization of the human p53 gene. Mol Cell Biol 6:1379−85.
- Lane, D., and E. Harlow. 1982. Two different viral transforming proteins bind the same host tumour antigen news. Nature 298:517.
- Lane, D. P. 1992. Cancer. p53, guardian of the genome news- comment. [see comments]. Nature 358:15−6.
- Lechner, M. S., and L. A. Laimins. 1994. Inhibition of p53 DNA binding by human papillomavirus E6 proteins. J Virol 68:4262−73.
- Lee, F., R. Mulligan, P. Berg, and G. Ringold. 1981. Glucocorticoids regulate expression of dihydrofolate reductase cDNA in mouse mammary tumour virus chimaeric plasmids. Nature 294:228−32.
- Lee, J. M. 1998. Inhibition of p53-dependent apoptosis by the KIT tyrosine kinase: regulation of mitochondrial permeability transition and reactive oxygen species generation. Oncogene 17:1653−62.
- Lee, J. M., J. L. Abrahamson, R. Kandel, L. A. Donehower, and A. Bernstein. 1994. Susceptibility to radiation-carcinogenesis and accumulation of chromosomal breakage in p53 deficient mice. Oncogene 9:3731−6.
- Lees-Miller, S. P., Y. R. Chen, and C. W. Anderson. 1990. Human cells contain a DNA-activated protein kinase that phosphorylates simian virus 40 T antigen, mouse p53, and the human Ku autoantigen. Mol Cell Biol 10:6472−81.
- Lees-Miller, S. P., K. Sakaguchi, S. J. Ullrich, E. Appella, and C. W. Anderson. 1992 Human DNA-activated protein kinase phosphorylates serines 15 and 37 in the amino-terminal transactivation domain of human p53. Mol Cell Biol 12:5041−9.
- Lehar, S. M., M. Nacht, T. Jacks, C. A. Vater, T. Chittenden, and B. C. Guild. 1996 Identification and cloning of EI24, a gene induced by p53 in etoposide- treated cells. Oncogene 12:1181−7.
- Li, B., J. M. Rosen, J. McMenamin-Balano, W. J. Muller, and A. S. Perkins. 1997 neu/ERBB2 cooperates with p53−172H during mammary tumorigenesis in transgenic mice. Mol Cell Biol 17:3155−63.
- Lill, N. L., S. R. Grossman, D. Ginsberg, J. DeCaprio, and D. M. Livingston. 1997 Binding and modulation of p53 by p300/CBP coactivators. Nature 387:823−7.
- Lin, J., J. Chen, B. Elenbaas, and A. J. Levine. 1994. Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein. Genes Dev 8:1235−46.
- Lin, J., A. K. Teresky, and A. J. Levine. 1995. Two critical hydrophobic amino acids in the N-terminal domain of the p53 protein are required for the gain of function phenotypes of human p53 mutants. Oncogene 10:2387−90.
- Livingstone, L. R., A. White, J. Sprouse, E. Livanos, T. Jacks, and T. D. Tlsty. 1992 Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell 70:923−35.
- Ljungman, M., and F. Zhang. 1996. Blockage of RNA polymerase as a possible trigger for u.v. light-induced apoptosis. Oncogene 13:823−31.
- Lopes, U. G., P. Erhardt, R. Yao, and G. M. Cooper. 1997. p53-dependent induction of apoptosis by proteasome inhibitors. J Biol Chem 272:12 893−6.
- Lotem, J., and L. Sachs. 1995. Interferon-gamma inhibits apoptosis induced by wild-type p53, cytotoxic anti-cancer agents and viability factor deprivation in myeloid cells. Leukemia 9:685−92.
- Lowe, S. W., S. Bodis, N. Bardeesy, A. McClatchey, L. Remington, H. E. Ruley, D. E. Fisher, T. Jacks, J. Pelletier, and D. E. Housman. 1994. Apoptosis and the prognostic significance ofp53 mutation. Cold Spring Harb Symp Quant Biol 59:419−26.
- Lowe, S. W., T. Jacks, D. E. Housman, and H. E. Ruley. 1994. Abrogation of oncogene-associated apoptosis allows transformation of p53-deficient cells. Proc Natl Acad Sci U S A 91:2026−30.
- Lu, H., and A. J. Levine. 1995. Human TAFII31 protein is a transcriptional coactivator of the p53 protein. Proc Natl Acad Sci U S A 92:5154−8.
- Lu, H., J. Lin, J. Chen, and A. J. Levine. 1994. The regulation of p53-mediated transcription and the roles of hTAFII31 and mdm-2. Harvey Lect 90:81−93.
- Mack, D. H., J. Vartikar, J. M. Pipas, and L. A. Laimins. 1993. Specific repression of TATA-mediated but not initiator-mediated transcription by wild-type p53. Nature 363:281−3.
- Mansur, C. P., B. Marcus, S. Dalai, and E. J. Androphy. 1995 The domain of p53 required for binding HPV 16 E6 is separable from the degradation domain. Oncogene 10:457−65.
- Marchetti, P., M. Castedo, S. A. Susin, N. Zamzami, T. Hirsch, A. Macho, A. Haeffner, F. Hirsch, M. Geuskens, and G. Kroemer. 1996. Mitochondrial permeability transition is a central coordinating event of apoptosis. J Exp Med 184:1155−60.
- Marsters, S. A., J. P. Sheridan, R. M. Pitti, J. Brush, A. Goddard, and A. Ashkenazi. 1998. Identification of a ligand for the death-domain-containing receptor Apo3. Curr Biol 8:525−8.
- Martin, K., D. Trouche, C. Hagemeier, and T. Kouzarides. 1995. Regulation of transcription by E2F1/DP1. J Cell Sci Suppl 19:91−4.
- Matsuzawa, S., S. Takayama, B. A. Froesch, J. M. Zapata, and J. C. Reed. 1998 p53-inducible human homologue of Drosophila seven in absentia (Siah) inhibits cell growth: suppression by BAG-1. Embo J 17:2736−47.
- Meek, D. W. 1997. Post-translational modification of p53 and the integration of stress signals. Pathol Biol (Paris) 45:804−14.
- Midgley, C. A., and D. P. Lane. 1997. p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding. Oncogene 15:1179−89.
- Miller, C. W., A. Chumakov, J. Said, D. L. Chen, A. Aslo, and H. P. Koeffler. 1993 Mutant p53 proteins have diverse intracellular abilities to oligomerize and activate transcription. Oncogene 8:1815−24.
- Milne, D. M., D. G. Campbell, F. B. Caudwell, and D. W. Meek. 1994. Phosphorylation of the tumor suppressor protein p53 by mitogen- activated protein kinases. J Biol Chem 269:925 360.
- Milne, D. M., R. H. Palmer, D. G. Campbell, and D. W. Meek. 1992 Phosphorylation of the p53 tumour-suppressor protein at three N- terminal sites by a novel casein kinase I-like enzyme. Oncogene 7:1361−9.
- Milner, J. 1995. Flexibility: the key to p53 function? Trends Biochem Sci 20:49−51.
- Milner, J., and E. A. Medcalf. 1991. Cotranslation of activated mutant p53 with wild type drives the wild- type p53 protein into the mutant conformation. Cell 65:765−74.
- Milner, J., and E. A. Medcalf. 1990. Temperature-dependent switching between «wildtype» and «mutant» forms of p53-Vall35. JMol Biol 216:481−4.
- Milner, J., E. A. Medcalf, and A. C. Cook. 1991. Tumor suppressor p53: analysis of wildtype and mutant p53 complexes. Mol Cell Biol 11:12−9.
- Minna, J. D., J. Schutte, J. Viallet, F. Thomas, F. J. Kaye, T. Takahashi, M. Nau, J. Whang-Peng, M. Birrer, and A. F. Gazdar. 1989. Transcription factors and recessive oncogenes in the pathogenesis of human lung cancer. Int J Cancer Suppl 4:32−4.
- Miyashita, T., S. Krajewski, M. Krajewska, H. G. Wang, H. K. Lin, D. A. Liebermann, B. Hoffman, and J. C. Reed. 1994. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 9:1799−805.
- Miyashita, T., and J. C. Reed. 1995. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80:293−9.
- Muller, B. F., D. Paulsen, and W. Deppert. 1996. Specific binding of MAR/SAR DNAelements by mutant p53. Oncogene 12:1941−52.
- Nacht, M., A. Strasser, Y. R. Chan, A. W. Harris, M. Schlissel, R. T. Bronson, and T. Jacks. 1996. Mutations in the p53 and SCID genes cooperate in tumorigenesis. Genes Dev 10:2055−66.
- Nelson, W. G., and M. B. Kastan. 1994. DNA strand breaks: the DNA template alterations that trigger p53- dependent DNA damage response pathways. Mol Cell Biol 14:181 523.
- Nguyen, K. T., B. Liu, K. Ueda, M. M. Gottesman, I. Pastan, and K. V. Chin. 1994 Transactivation of the human multidrug resistance (MDR1) gene promoter by p53 mutants. Oncol Res 6:71−7.
- Niewolik, D., Π. Vojtesek, and J. Kovarik. 1995. p53 derived from human tumour cell lines and containing distinct point mutations can be activated to bind its consensus target sequence. Oncogene 10:881−90.
- Nigro, J. M., S. J. Baker, A. C. Preisinger, J. M. Jessup, R. Hostetter, K. Cleary, S. H. Bigner, N. Davidson, S. Baylin, P. Devilee, and et al. 1989. Mutations in the p53 gene occur in diverse human tumour types. Nature 342:705−8.
- Oliner, J. D. 1993. Discerning the function of p53 by examining its molecular interactions. Bioessays 15:703−7.
- Osifchin, N. E., D. Jiang, N. Ohtani-Fujita, T. Fujita, M. Carroza, S. J. Kim, T. Sakai, and P. D. Robbins. 1994. Identification of a p53 binding site in the human retinoblastoma susceptibility gene promoter. J Biol Chem 269:6383−9.
- ΠΡΠΎΠ²ΡΠΊΠ°Ρ, Π. Π‘., Π. Π. ΠΠΎΠΏΠ½ΠΈΠ½, Π. Π’. Π Π°ΠΉΡ Π»ΠΈΠ½, Π. Π‘ΠΌΠΈΡΠ½ΠΎΠ²Π°, Π. Π‘. ΠΡΠ°ΡΠΎΠ»ΠΎΠ², Π. Π. Π§ΡΠΌΠ°ΠΊΠΎΠ². 1995. ΠΠ»ΠΈΡΠ½ΠΈΠ΅ Π½Π° ΡΠ°Π·Π»ΠΈΡΠ½ΡΠ΅ Π»ΠΈΠ½ΠΈΠΈ ΠΊΠ»Π΅ΡΠΎΠΊ ΠΊΠΠΠ Ρ53, ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΡΡΠ΅ΠΌΠΎΠΉ ΠΏΠΎΠ΄ ΠΊΠΎΠ½ΡΡΠΎΠ»Π΅ΠΌ ΡΠΊΠ·ΠΎΠ³Π΅Π½Π½ΠΎΠ³ΠΎ Π³ΠΎΠΌΠΎΠ»ΠΎΠ³ΠΈΡΠ½ΠΎΠ³ΠΎ ΠΏΡΠΎΠΌΠΎΡΠΎΡΠ°. ΠΠΎΠ»Π΅ΠΊΡΠ»ΡΡΠ½Π°Ρ Π±ΠΈΠΎΠ»ΠΎΠ³ΠΈΡ 29:61−70.
- Ouchi, Π’., Π. N. Monteiro, A. August, S. A. Aaronson, and Π. Hanafusa. 1998 BRCA1 regulates p53-dependent gene expression. Proc Natl Acad Sci U S A 95:2302−6.
- Parada, L. F., H. Land, R A. Weinberg, D. Wolf, and V. Rotter. 1984. Cooperation between gene encoding p53 tumour antigen and ras in cellular transformation. Nature 312:649−51.
- Pear, W. S., G. P. Nolan, M. L. Scott, and D. Baltimore. 1993. Production of high-titer helper-free retroviruses by transient transfection. Proc Natl Acad Sci U S A 90:8392−6.
- Picksley, S. M., B. Vojtesek, A. Sparks, and D. P. Lane. 1994. Immunochemical analysis of the interaction of p53 with MDM2-~fine mapping of the MDM2 binding site on p53 using synthetic peptides. Oncogene 9:2523−9.
- Pietenpol, J. A., T. Tokino, S. Thiagalingam, W. S. el-Deiry, K. W. Kinzler, and B. Vogelstein. 1994. Sequence-specific transcriptional activation is essential for growth suppression by p53. Proc Natl Acad Sci U S A 91:1998−2002.
- Polyak, K., Y. Xia, J. L. Zweier, K. W. Kinzler, and B. Vogelstein. 1997 A model for p53-induced apoptosis see comments. Nature 389:300−5.
- Prasolov, V. S., and P. M. Chumakov. 1988. Antisense RNA p53 inhibits proliferation of normal and transformed cells., Mol Biol (Mosk) 22:1371−80.
- Prives, C., and J. J. Manfredi. 1993. The p53 tumor suppressor protein: meeting review. Genes Dev 7:529−34.
- Quelle, F. W., J. Wang, J. Feng, D. Wang, J. L. Cleveland, J. N. Ihle, and G. P. Zambetti. 1998. Cytokine rescue of p53-dependent apoptosis and cell cycle arrest is mediated by distinct Jak kinase signaling pathways. Genes Dev 12:1099−107.
- Querido, E., J. G. Teodoro, and P. E. Branton. 1997. Accumulation of p53 induced by the adenovirus El A protein requires regions involved in the stimulation of DNA synthesis. J Virol 71:3526−33.
- Radfar, A., I. Unnikrishnan, H. W. Lee, R. A. DePinho, and N. Rosenberg. 1998 pl9(Arf) induces p53-dependent apoptosis during abelson virus-mediated pre-B cell transformation. ProcNatl Acad Sci U S A 95:13 194−9.
- Raycroft, L., J. R Schmidt, K, Yoas, M. M. Hao, and G. Lozano. 1991. Analysis of p53 mutants for transcriptional activity. Mol Cell Biol 11:6067−74.
- Reinke, V., and G. Lozano. 1997. The p53 targets mdm2 and Fas are not required as mediators of apoptosis in vivo. Oncogene 15:1527−34.
- Reisman, D., N. B. Elkind, B. Roy, J. Beamon, and V. Rotter. 1993 c-Myc trans-activates the p53 promoter through a required downstream CACGTG motif. Cell Growth Differ 4:57−65.
- Rotter, V., R. Aloni-Grinstein, D. Schwartz, N. B. Elkind, A. Simons, R. Wolkowicz, M. Lavigne, P. Beserman, A. Kapon, and N. Goldfinger. 1994. Does wild-type p53 play a role in normal cell differentiation? Semin Cancer Biol 5:229−36.
- Roy, B., J. Beamon, E. Balint, and D. Reisman. 1994. Transactivation of the human p53 tumor suppressor gene by c-Myc/Max contributes to elevated mutant p53 expression in some tumors. Mol Cell Biol 14:7805−15.
- Ruaro, E. M., L. Collavin, G. Del Sal, R. Haffner, M. Oren, A. J. Levine, and C. Schneider. 1997. A proline-rich motif in p53 is required for transactivation-independent growth arrest as induced by Gasl. Proc Natl Acad Sci U S A 94:4675−80.
- Ryan, J. J., and M. F. Clarke. 1994. Alteration of p53 conformation and induction of apoptosis in a murine erythroleukemia cell line by dimethylsulfoxide. Leuk Res 18:617−21.
- Ryan, J. J., E. Prochownik, C. A. Gottlieb, I. J. Apel, R. Merino, G. Nunez, and M. F. Clarke. 1994. c-myc and bcl-2 modulate p53 function by altering p53 subcellular trafficking during the cell cycle. Proc Natl Acad Sci U S A 91:5878−82.
- Ryan, K. M., and K. H. Vousden. 1998. Characterization of structural p53 mutants which show selective defects in apoptosis but not cell cycle arrest. Mol Cell Biol 18:3692−8.
- Sabbatini, P., S. K. Chiou, L. Rao, and E. White. 1995. Modulation of p53-mediated transcriptional repression and apoptosis by the adenovirus E1B 19K protein. Mol Cell Biol 15:1060−70.
- Sakaguchi, K., J. E. Herrera, S. Saito, T. Miki, M. Bustin, A. Vassilev, C. W. Anderson, and E. Appella. 1998. DNA damage activates p53 through a phosphorylation-acetylation cascade. Genes Dev 12:2831−41.
- Sakamuro, D., P. Sabbatini, E. White, and G. C. Prendergast. 1997 The polyproline region of p53 is required to activate apoptosis but not growth arrest. Oncogene 15:887−98.
- Sambrook, J., E. Fritsch, and T. Maniatis. 1989. Molecular Cloning. Cold Spring Harbor Laboratory Press, New York.
- Samuelson, A. V., and S. W. Lowe. 1997. Selective induction of p53 and chemosensitivity in RB-deficient cells by El A mutants unable to bind the RB-related proteins. Proc Natl Acad Sci U S A 94:12 094−9.
- Scheffner, M., J. M. Huibregtse, R. D. Vierstra, and P. M. Howley. 1993 The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 75:495−505.
- Scheffner, M., U. Nuber, and J. M. Huibregtse. 1995. Protein ubiquitination involving an E1-E2-E3 enzyme ubiquitin thioester cascade. Nature 373:81−3.
- Scheffner, M., B. A. Werness, J. M. Huibregtse, A. J. Levine, and P. M. Howley. 1990 The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63:1129−36.
- Schneider, E., M. Montenarh, and P. Wagner. 1998. Regulation of CAK kinase activity by p53 In Process Citation., Oncogene 17:2733−41.
- Selivanova, G., V. Iotsova, I. Okan, M. Fritsche, M. Strom, B. Groner, R. C. Grafstrom, and K. G. Wiman. 1997. Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain. Nat Med 3:632−8.
- Serrano, M., A. W. Lin, M. E. McCurrach, D. Beach, and S. W. Lowe. 1997 Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and pl6INK4a. Cell 88:593−602.
- Seto, E., A. Usheva, G. P. Zambetti, J. Momand, N. Horikoshi, R. Weinmann, A. J. Levine, and T. Shenk. 1992. Wild-type p53 binds to the TATA-binding protein and represses transcription. Proc Natl Acad Sci U S A 89:12 028−32.
- Shaulian, E., I. Haviv, Y. Shaul, and M. Oren. 1995. Transcriptional repression by the C-terminal domain of p53. Oncogene 10:671−80.
- Shaulian, E., A. Zauberman, D. Ginsberg, and M. Oren. 1992. Identification of a minimal transforming domain of p53: negative dominance through abrogation of sequence-specific DNA binding. Mol Cell Biol 12:5581−92.
- Shaulsky, G., A. Ben-Ze'ev, and V. Rotter. 1990. Subcellular distribution of the p53 protein during the cell cycle ofBalb/c 3T3 cells. Oncogene 5:1707−11.
- Shieh, S. Y., M. Ikeda, Y. Taya, and C. Prives. 1997. DNA damage-induced phosphorylation ofp53 alleviates inhibition by MDM2. Cell 91:325−34.
- Soussi, T., C. Caron de Fromentel, and P. May. 1990. Structural aspects of the p53 protein in relation to gene evolution. Oncogene 5:945−52.
- Srivastava, S., Z. Q. Zou, K. Pirollo, W. Blattner, and E. H. Chang. 1990 Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome see comments. Nature 348:747−9.
- Stewart, N., G. G. Hicks, F. Paraskevas, and M. Mowat. 1995. Evidence for a second cell cycle block at G2/M by p53. Oncogene 10:109−15.
- Sturzbecher, H. W., C. Addison, and J. R. Jenkins. 1988. Characterization of mutant p53-hsp72/73 protein-protein complexes by transient expression in monkey COS cells. Mol Cell Biol 8:3740−7.
- Sturzbecher, H. W., R. Brain, C. Addison, K. Rudge, M. Remm, M. Grimaldi, E. Keenan, and J. R. Jenkins. 1992. A C-terminal alpha-helix plus basic region motif is the major structural determinant of p53 tetramerization. Oncogene 7:1513−23.
- Sturzbecher, H. W., P. Chumakov, W. J. Welch, and J. R. Jenkins. 1987 Mutant p53 proteins bind hsp 72/73 cellular heat shock-related proteins in SV40-transformed monkey cells. Oncogene 1:201−11.
- Subler, M. A., D. W. Martin, and S. Deb. 1994. Activation of the human immunodeficiency virus type 1 long terminal repeat by transforming mutants of human p53. J Virol 68:103−10.
- Subler, M. A., D. W. Martin, and S. Deb. 1994. Overlapping domains on the p53 protein regulate its transcriptional activation and repression functions. Oncogene 9:1351−9.
- Sullivan, G. F., P. S. Amenta, J. D. Villanueva, C. J. Alvarez, J. M. Yang, and W. N. Hait. 1998. The expression of drug resistance gene products during the progression of human prostate cancer. Clin Cancer Res 4:1393−403.
- Tahara, H., E. Sato, A. Noda, and T. Ide. 1995. Increase in expression level of p21sdil/cipl/wafl with increasing division age in both normal and SV40-transformed human fibroblasts. Oncogene 10:835−40.
- Takahashi, T., H. Suzuki, T. Hida, Y. Sekido, Y. Ariyoshi, and R. Ueda. 1991 The p53 gene is very frequently mutated in small-cell lung cancer with a distinct nucleotide substitution pattern. Oncogene 6:1775−8.
- Thut, C. J., J. L. Chen, R. Klemm, and R. Tjian. 1995. p53 transcriptional activation mediated by coactivators TAFII40 and TAFII60. Science 267:100−4.
- Ullrich, S. J., W. E. Mercer, and E. Appella. 1992. Human wild-type p53 adopts a unique conformational and phosphorylation state in vivo during growth arrest of glioblastoma cells. Oncogene 7:1635−43.
- Unger, T., J. A. Mietz, M. Scheffner, C. L. Yee, and P. M. Howley. 1993 Functional domains of wild-type and mutant p53 proteins involved in transcriptional regulation, transdominant inhibition, and transformation suppression. Mol Cell Biol 13:5186−94.
- Vojtesek, B., and D. P. Lane. 1993. Regulation of p53 protein expression in human breast cancer cell lines. J Cell Sci 105:607−12.
- Vousden, K. H., B. Vojtesek, C. Fisher, and D. Lane. 1993. HPV-16 E7 or adenovirus El A can overcome the growth arrest of cells immortalized with a temperature-sensitive p53. Oncogene 8:1697−702.
- Waga, S., G. J. Hannon, D. Beach, and B. Stillman. 1994. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA see comments. Nature 369:574−8.
- Wagner, A. J., J. M. Kokontis, and N. Hay. 1994. Myc-mediated apoptosis requires wildtype p53 in a manner independent of cell cycle arrest and the ability of p53 to induce p21wafl/cipl. Genes Dev 8:2817−30.
- Walker, K. K., and A. J. Levine. 1996. Identification of a novel p53 functional domain that is necessary for efficient growth suppression. Proc Natl Acad Sci U S A 93:15 335−40.
- Wang, Q., G. P. Zambetti, and D. P. Suttle. 1997. Inhibition of DNA topoisomerase II alpha gene expression by the p53 tumor suppressor. Mol Cell Biol 17:389−97.
- Wang, X. W., H. Yeh, L. Schaeffer, R. Roy, V. Moncollin, J. M. Egly, Z. Wang, E. C. Freidberg, M. K. Evans, B. G. Taffe, and et al. 1995. p53 modulation of TFIM-associated nucleotide excision repair activity. Nat Genet 10:188−95.
- Werness, B. A., A. J. Levine, and P. M. Howley. 1990. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 248:76−9.
- White, E. 1994. Tumour biology. p53, guardian of Rb news- comment. Nature 371:21−2.
- Wieczorek, A. M., J. L. Waterman, M. J. Waterman, and T. D. Halazonetis. 1996. Structure-based rescue of common tumor-derived p53 mutants. Nat Med 2:1143−6.
- Wu, G. S., P. Saftig, C. Peters, and W. S. El-Deiry. 1998. Potential role for cathepsin D in p53-dependent tumor suppression and chemosensitivity. Oncogene 16:2177−83.
- Wu, H., and G. Lozano. 1994. NF-kappa B activation of p53. A potential mechanism for suppressing cell growth in response to stress. J Biol Chem 269:20 067−74.
- Xiao, Z. X., J. Chen, A. J. Levine, N. Modjtahedi, J. Xing, W. R. Sellers, and D. M. Livingston. 1995. Interaction between the retinoblastoma protein and the oncoprotein MDM2. Nature 375:694−8.
- Xu, Y., and D. Baltimore. 1996. Dual roles of ATM in the cellular response to radiation and in cell growth control see comments. Genes Dev 10:2401−10.
- Yeung, M. C., and A. S. Lau. 1998. Tumor suppressor p53 as a component of the tumor necrosis factor- induced, protein kinase PKR-mediated apoptotic pathway in human promonocyte U937 cells. J Biol Chem 273:25 198−202.
- Yew, P. R., and A. J. Berk. 1992. Inhibition of p53 transactivation required for transformation by adenovirus early IB protein. Nature 357:82−5.
- Yewdell, J. W., J. V. Gannon, and D. P. Lane. 1986. Monoclonal antibody analysis of p53 expression in normal and transformed cells. J Virol 59:444−52.
- Yin, Y., M. A. Tainsky, F. Z. Bischoff, L. C. Strong, and G. M. Wahl. 1992 Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell 70:937−48.
- Yin, Y., Y. Terauchi, G. G. Solomon, S. Aizawa, P. N. Rangarajan, Y. Yazaki, T. Kadowaki, and J. C. Barrett. 1998. Involvement of p85 in p53-dependent apoptotic response to oxidative stress. Nature 391:707−10.
- Yonish-Rouach, E., D. Resnitzky, J. Lotem, L. Sachs, A. Kimchi, and M. Oren. 1991. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature 352:345−7.
- Zerrahn, J., W. Deppert, D. Weidemann, T. Patschinsky, F. Richards, and J. Milner.1992. Correlation between the conformational phenotype of p53 and its subcellular location. Oncogene 7:1371−81.
- Zhan, Q., U. Kontny, M. Iglesias, I. Alamo, Jr., K. Yu, M. C. Hollander, C. D. Woodworth, and A. J. Fornace, Jr. 1999. Inhibitory effect of Bcl-2 on p53-mediated transactivation following genotoxic stress. Oncogene 18:297−304.
- Zhang, S. Y., B. Ruggeri, P. Agarwal, A. F. Sorling, T. Obara, H. Ura, M. Namiki, and A. J. Klein-Szanto. 1994. Immunohistochemical analysis of p53 expression in human pancreatic carcinomas. Arch Pathol Lab Med 118:150−4.
- Zhang, W., X. Y. Guo, and A. B. Deisseroth. 1994. The requirement of the carboxyl terminus of p53 for DNA binding and transcriptional activation depends on the specific p53 binding DNA element. Oncogene 9:2513−21.
- Zhang, W., G. Hu, E. Estey, J. Hester, and A. Deisseroth. 1992. Altered conformation of the p53 protein in myeloid leukemia cells and mitogen-stimulated normal blood cells. Oncogene 7:1645−7.
- Zhang, Y., Y. Xiong, and W. G. Yarbrough. 1998. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 92:725−34.
- Zhu, J., W. Zhou, J. Jiang, and X. Chen. 1998. Identification of a novel p53 functional domain that is necessary for mediating apoptosis. J Biol Chem 273:13 030−6.
- Zindy, F., C. M. Eischen, D. H. Randle, T. Kamijo, J. L. Cleveland, C. J. Sherr, and M. F. Roussel. 1998. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev 12:2424−33.